Life Sciences at Goldman Sachs Alternatives led a $75m Series C round in Beacon Therapeutics.

Life Sciences at Goldman Sachs Alternatives, a specialized private equity and growth investment strategy within Goldman Sachs, led a $75m Series C round in Beacon Therapeutics, a clinical-stage biotechnology company, with participation from Retinal Degeneration Fund, Syncona Limited, Forbion, Oxford Science Enterprises, and Advent Life Sciences. “This significant fundraising, led by new blue-chip investor Life Sciences at Goldman Sachs Alternatives, validates our strategy to save and restore sight for people living with rare and prevalent ocular diseases. With pivotal laru-zova data expected in the second half of 2026, these funds will accelerate our commercial preparations for this potentially life-changing product, as well as advance and expand our pipeline. We thank our new and existing investors for their confidence in our mission to deliver lasting impact in blinding ocular diseases," Lance Baldo, Beacon Therapeutics CEO.